Failure of erythromycin to eliminate airway colonization with ureaplasma urealyticum in very low birth weight infants

被引:34
作者
R John Baier
John Loggins
Thomas E Kruger
机构
[1] Department of Pediatrics, Louisiana State University, Health Sciences Center, Shreveport, LA 71130-3932
[2] Louisiana State University, Health Sciences Center, Shreveport, LA 71130-3932
关键词
Erythromycin; Neonatal Intensive Care Unit; Chronic Lung Disease; Macrolide Antibiotic; Ureaplasma Urealyticum;
D O I
10.1186/1471-2431-3-10
中图分类号
学科分类号
摘要
Background: Airway colonization of mechanically ventilated very low birth weight infants (birth weight < 1500 grams) by Ureaplasma urealyticum (Uu) is associated with an increased risk of bronchopulmonary dysplasia (BPD). While Uu is sensitive to erythromycin in vitro, the efficacy of intravenous (IV) erythromycin to eliminate Uu from the airways has not been studied. Methods: 17 very low birth weight infants with Uu positive tracheal aspirate (TA) cultures were randomized to either 5 (8 infants) or 10 days (9 infants) of IV erythromycin lactobionate (40 mg/kg/day in 3 divided doses). Tracheal aspirate cultures for Uu were performed on days 0, 5, 10 and 15. Results: Intravenous erythromycin failed to eliminate airway colonization in a large proportion of infants regardless of whether they received 5 or 10 days of treatment. Ureaplasma urealyticum was isolated from 4/15 (27%) of TAs obtained at 5 days, 5/12 TAs (42%) obtained at 10 days and 6/11(55%) TAs obtained at 15 days (combined group data). Conclusions: Erythromycin administered IV does not eliminate Uu from the airways in a large proportion of infants. Failure of erythromycin to eliminate Uu from the airways may contribute to the lack of efficacy of this drug in reducing the incidence of BPD in very low birth weight infants. © 2003 Baier et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 19 条
[1]  
Cassell G.H., Waites K.B., Crouse D.T., Rudd P.T., Canupp K.C., Stagno S., Cutter G.R., Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants, Lancet, 2, pp. 240-245, (1988)
[2]  
Wang E.E., Frayha H., Watts J., Hammerberg O., Chernesky M.A., Mahony J.B., Cassell G.H., Role of Ureaplasma urealyticum and other pathogens in the development of chronic lung disease of prematurity, Pediatr. Infect. Dis. J., 7, pp. 547-551, (1988)
[3]  
Wang E.E., Ohlsson A., Kellner J.D., Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: Results of a metaanalysis, J. Pediatr., 127, pp. 640-644, (1995)
[4]  
Baier R.J., Loggins J., Kruger T.E., Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia: Relation to isolation of Ureaplasma urealyticum, J. Investig. Med., 49, pp. 362-369, (2001)
[5]  
Waites K.B., Crouse D.T., Cassell G.H., Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates, Pediatr. Infect. Dis. J., 11, pp. 23-29, (1992)
[6]  
Patterson A.M., Taciak V., Lovchik J., Fox R.E., Campbell A.B., Viscardi R.M., Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants, Pediatr. Infect. Dis. J., 17, pp. 321-328, (1998)
[7]  
Matlow A., Th'ng C., Kovach D., Quinn P., Dunn M., Wang E., Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents, Antimicrob. Agents Chemother., 42, pp. 1290-1292, (1998)
[8]  
Renaudin H., Bebear C., Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum, Eur. J. Clin. Microbiol. Infect. Dis., 9, pp. 838-841, (1990)
[9]  
Renaudin H., Bebear C., Robertson J.A., In vitro susceptibility of tetracycline-resistant strains of Ureaplasma urealyticum to newer macrolides and quinolones, and a streptogramin, Eur. J. Clin. Microbiol. Infect. Dis., 10, pp. 984-986, (1991)
[10]  
Lyon A.J., McColm J., Middlemist L., Fergusson S., McIntosh N., Ross P.W., Randomised trial of erythromycin on the development of chronic lung disease in preterm infants, Arch. Dis. Child Fetal Neonatal Ed., 78, (1998)